Lovastatin treatment improves defect mineralisation in Nf1Prx1 mice. (A) Transverse micro computed tomography sections of the injury 14 days post induction. Quantification of the mineralised matrix in the cortical regions (red region of interest (ROI)) and bone marrow shaft (green ROI) 7 days (n = 3) and 14 days (n = 6) post injury. Note the increased bone volume to total volume (BV/TV) in the bone marrow cavity (left chart) as well as in the cortical region (right chart) in animals treated for 7 and 14 days with lovastatin as compared with controls. (B) Analysis of the mitogen activated protein kinase (MAPK) pathway activation status (pErk1/Erk1 ratio) in calvaria bones of Nf1Prx1 mice and lovastatin-treated mice. The MAPK pathway activation was determined by densitometric analysis of the western blots.